ID   OHRI-MEL-13
AC   CVCL_A4BI
SY   Ottawa Hospital Research Institute-MELanoma-13
DR   ATCC; CRL-3427
DR   cancercelllines; CVCL_A4BI
DR   Wikidata; Q105510486
RX   PubMed=33555379;
CC   Population: Caucasian.
CC   Doubling time: 42 hours (PubMed=33555379).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Lys601Asn (c.1803A>T); ClinVar=VCV000376285; Zygosity=Homozygous (PubMed=33555379).
CC   Derived from site: Metastatic; Pelvic lymph node; UBERON=UBERON_0015876.
ST   Source(s): ATCC=CRL-3427
ST   Amelogenin: X,Y
ST   CSF1PO: 9,12
ST   D13S317: 12
ST   D16S539: 12
ST   D5S818: 9,11
ST   D7S820: 9,11
ST   TH01: 6,9.3
ST   TPOX: 8,10
ST   vWA: 13,19
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   59Y
CA   Cancer cell line
DT   Created: 12-01-21; Last updated: 19-12-24; Version: 7
//
RX   PubMed=33555379; DOI=10.1007/s00432-021-03545-2;
RA   Keller B.A., Laight B.J., Varette O., Broom A., Wedge M.-E.,
RA   McSweeney B., Cemeus C., Petryk J., Lo B., Burns B., Nessim C.,
RA   Ong M., Chica R.A., Atkins H.L., Diallo J.-S., Ilkow C.S., Bell J.C.;
RT   "Personalized oncology and BRAF(K601N) melanoma: model development,
RT   drug discovery, and clinical correlation.";
RL   J. Cancer Res. Clin. Oncol. 147:1365-1378(2021).
//